Patent classifications
C07D307/16
HDAC6 selective inhibitors, preparation method therefor, and application thereof
Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof. ##STR00001##
Sulfide alkyl compounds for HBV treatment
The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
Sulfide alkyl compounds for HBV treatment
The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
Biodegradable compound, lipid particle, composition containing lipid particle, and kit
The compound according to the present embodiment is represented by the following formula (1):
Q-L-CHR.sub.2(1)
(wherein, Q is a non-cationic aliphatic group that does not contain nitrogen but contains oxy; L is a single bond or an aliphatic group containing no nitrogen; Rs are C.sub.12-C.sub.24 aliphatic group, the same or different; and at least one R contains, in the main chain or side chain thereof, a linking group L.sup.R selected from the group consisting of C(O)O, OC(O), OC(O)O, SC(O), C(O)S, C(O)NH, and NHC(O)).
Biodegradable compound, lipid particle, composition containing lipid particle, and kit
The compound according to the present embodiment is represented by the following formula (1):
Q-L-CHR.sub.2(1)
(wherein, Q is a non-cationic aliphatic group that does not contain nitrogen but contains oxy; L is a single bond or an aliphatic group containing no nitrogen; Rs are C.sub.12-C.sub.24 aliphatic group, the same or different; and at least one R contains, in the main chain or side chain thereof, a linking group L.sup.R selected from the group consisting of C(O)O, OC(O), OC(O)O, SC(O), C(O)S, C(O)NH, and NHC(O)).
HDAC6 Selective Inhibitors, Preparation Method Therefor, and Application Thereof
Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.
##STR00001##
STAT3 transcription factor inhibitors and methods of using the same
Compounds that inhibit the activity of Signal transducer and activator of transcription 3 (STAT3), or pharmaceutically acceptable salts or prodrugs thereof, and methods of using these compounds to treat cancer and other diseases.
STAT3 transcription factor inhibitors and methods of using the same
Compounds that inhibit the activity of Signal transducer and activator of transcription 3 (STAT3), or pharmaceutically acceptable salts or prodrugs thereof, and methods of using these compounds to treat cancer and other diseases.
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.